4-Mar-2026
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Business Wire (Wed, 4-Mar 9:00 AM ET)
Business Wire (Tue, 3-Mar 10:00 AM ET)
Exact Sciences Stockholders Approve Acquisition by Abbott
Business Wire (Fri, 20-Feb 4:05 PM ET)
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
Business Wire (Fri, 13-Feb 4:05 PM ET)
Globe Newswire (Mon, 9-Feb 1:13 PM ET)
Halper Sadeh LLC is Investigating SKYT, EXAS, GORO, MOVE on Behalf of Shareholders
Globe Newswire (Tue, 3-Feb 3:05 PM ET)
Business Wire (Tue, 3-Feb 2:32 PM ET)
Oncotype DX Breast Recurrence Score Test Surpasses 2 Million Patients Worldwide
Business Wire (Tue, 3-Feb 9:03 AM ET)
Halper Sadeh LLC Reminds Shareholders of EXAS, DVN, NFBK of the Firm's Investigations
Globe Newswire (Mon, 2-Feb 5:16 PM ET)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS
PRNewswire (Mon, 2-Feb 3:30 PM ET)
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Exact Sciences trades on the NASDAQ stock market under the symbol EXAS.
As of March 4, 2026, EXAS stock price climbed to $103.50 with 1,849,044 million shares trading.
EXAS has a beta of 0.31, meaning it tends to be less sensitive to market movements. EXAS has a correlation of 0.01 to the broad based SPY ETF.
EXAS has a market cap of $19.76 billion. This is considered a Large Cap stock.
Last quarter Exact Sciences reported $878 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $18 million and missed earnings estimates by -$.29.
In the last 3 years, EXAS traded as high as $103.67 and as low as $38.81.
The top ETF exchange traded funds that EXAS belongs to (by Net Assets): VTI, VB, VBK, VXF, XBI.
EXAS has outperformed the market in the last year with a return of +112.2%, while the SPY ETF gained +18.6%. In the last 3 month period, EXAS beat the market returning +2.3%, while SPY returned +0.5%. However, in the most recent 2 weeks EXAS has underperformed the stock market by returning +0.1%, while SPY returned +0.3%.
EXAS support price is $103.14 and resistance is $103.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EXAS shares will trade within this expected range on the day.
